Skip to content

US · CDIO · BIOTECHNOLOGY

Cardio Diagnostics Holdings, Inc. (CDIO) intrinsic value and stock valuation

$1.60as of 2026-11-21 · Mkt cap 3.62M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cardio Diagnostics Holdings, Inc. DCF and intrinsic value

InvestorsCraft values CDIO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CDIO’s statements →

Cardio Diagnostics Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Chicago, IL 60654 cdio.ai

How the business is doing

Fiscal 2020–2025, USD

Revenue
$10K
20202025
Net income
-$-6.5M
20202025
Free cash flow
-$-5.91M
20202025
Total equity
$6.97M+158.8% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$10K$30K$20K$0.00$0.00
Operating income-$-6.48M-$-8.37M-$-7.24M-$-4.55M-$-620K
Net income-$-6.5M-$-8.38M-$-8.38M-$-4.66M-$-620K
EPSd-$-3.71M-$-311.64K-$-19.95M-$-1.51M-$-1.94M
Operating cash flow-$-5.73M-$-4.99M-$-5.67M-$-5.09M-$-590K
Capital expenditure-$-190K-$-400K-$-790K-$-80K-$-110K
Free cash flow-$-5.91M-$-5.4M-$-6.47M-$-5.09M-$-700K
Total assets$7.77M$10.6M$4.46M$6.25M$1.1M
Total debt$700K$970K$1.26M$850K$0.00
Net debt-$-4.42M-$-6.86M-$-20K-$-3.27M-$-510K
Total equity$6.97M$9.56M$2.96M$4.3M$1.07M
Cash and short-term investments$5.11M$7.83M$1.28M$4.12M$510K
Income statement
20252024202320222021
Revenue$10K$30K$20K$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$10K$30K$20K$0.00$0.00
Research and development expenses$640K$230K$150K$40K$30K
Selling, general and administrative expenses$5.79M$8.15M$7.1M$4.49M$570K
Other expenses$70K$20K$20K$20K$20K
Operating expenses$6.5M$8.4M$7.26M$4.55M$620K
Cost and expenses$6.5M$8.4M$7.26M$4.55M$620K
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$10K$20K$6.74M$0.00$0.00
Depreciation and amortization$400K$280K$110K$20K$20K
Ebitda-$-6.09M-$-8.09M-$-1.53M-$-4.64M-$-600K
Operating income-$-6.48M-$-8.37M-$-7.24M-$-4.55M-$-620K
Total other income/expenses, net-$-10K-$-20K-$-1.13M-$-110K$0.00
Income before tax-$-6.5M-$-8.38M-$-8.38M-$-4.66M-$-620K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.5M-$-8.38M-$-8.38M-$-4.66M-$-620K
Weighted average shares outstanding$1.75M$26.9M$420K$3.09M$320K
Weighted average diluted shares outstanding$1.75M$26.9M$420K$3.09M$320K
Balance sheet
20252024202320222021
Cash and short-term investments$5.11M$7.83M$1.28M$4.12M$510K
Net receivables$10K$20K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.92M$8.79M$2.77M$5.89M$800K
Property, plant and equipment, net$960K$1.11M$1.15M$0.00$0.00
Goodwill and intangible assets$870K$710K$540K$360K$300K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.85M$1.82M$1.7M$360K$300K
Total assets$7.77M$10.6M$4.46M$6.25M$1.1M
Accounts payable$100K$90K$240K$1.1M$30K
Short-term debt$510K$540K$600K$850K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$600K$630K$840K$1.95M$30K
Long-term debt$190K$430K$660K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$190K$430K$660K$0.00$0.00
Capital lease obligations$430K$660K$890K$0.00$0.00
Total liabilities$790K$1.06M$1.5M$1.95M$30K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-29.25M-$-22.75M-$-14.37M-$-5.99M-$-1.33M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$6.97M$9.56M$2.96M$4.3M$1.07M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$700K$970K$1.26M$850K$0.00
Net debt-$-4.42M-$-6.86M-$-20K-$-3.27M-$-510K
Cash flow statement
20252024202320222021
Net income-$-6.5M-$-8.38M-$-8.38M-$-4.66M-$-620K
Depreciation and amortization$160K$280K$110K$20K$20K
Stock-based compensation$110K$2.59M$1.28M$0.00$60K
Change in working capital$260K$520K$210K-$-560K-$-40K
Accounts receivable$10K-$-10K-$0.00$0.00-$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$10K$0.00$0.00$140K$0.00
Net cash provided by operating activities-$-5.73M-$-4.99M-$-5.67M-$-5.09M-$-590K
Investments in property, plant and equipment-$-190K-$-210K-$-600K-$-80K-$-110K
Acquisitions, net$0.00$0.00$0.00$140K-$-250K
Net cash used for investing activities-$-420K-$-400K-$-790K-$-370K-$-360K
Common stock issued$3.8M$12.6M$0.00$12M$1.12M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.43M$11.9M$3.63M$9.06M$1.23M
Net change in cash-$-2.72M$6.54M-$-2.83M$3.6M$280K
Cash at end of period$5.11M$7.83M$1.28M$4.12M$510K
Operating cash flow-$-5.73M-$-4.99M-$-5.67M-$-5.09M-$-590K
Capital expenditure-$-190K-$-400K-$-790K-$-80K-$-110K
Free cash flow-$-5.91M-$-5.4M-$-6.47M-$-5.09M-$-700K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cardio Diagnostics Holdings, Inc.

        Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.

        CEO
        Meeshanthini V. Dogan
        Employees
        15
        Beta
        2.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Cardio Diagnostics Holdings, Inc. (CDIO)?

        Cardio Diagnostics Holdings, Inc. (CDIO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CDIO undervalued?

        CDIO trades at a price of $1.60 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.